Key result
Beta-blockers bind Na+/K+-ATPase ouabain sites concentration-dependently, led by propranolol, metoprolol, and sotalol.
Why the study?
Beta-adrenoceptor blockers inhibit the Mg2+-dependent ATP-hydrolytic function of Na+/K+-ATPase, but it is unclear if this is due to binding at the digitalis glycoside receptor sites.
Beta-blockers can bind to the same Na+/K+-ATPase receptor sites as digitalis glycosides, which may explain some of their proarrhythmic effects.
Beta-blockers displace ouabain from myocardial Na+/K+-ATPase in vitro; leaves open relevance to clinical cardiac effects.
We reported in a previous study that beta-adrenoceptor blockers inhibit the Mg2+-dependent ATP-hydrolytic function of Na+/K+-ATPase. To determine if this action is a result of binding of beta-blockers to the receptor sites that bind the digitalis glycosides, we performed displacement binding assays of eight beta-blockers with [3H]-ouabain (OUA) in guinea pig myocardial microsomal preparations. In the first series of experiments, 10-200 microM of the beta-blockers were displaced with 250 nM OUA. In the second set of experiments, 10-500 nM of OUA was displaced using 200 microM of the beta-blockers. The drugs showed concentration-dependent receptor occupancy at the different OUA levels. Propranolol (PPN), metoprolol (MTP), and sotalol (STL) showed the strongest binding; nadolol (NDL), indenolol (IDN), and atenolol (ATN) had intermediate binding; carazolol (CRZ) and celiprolol (CLP) had the weakest binding properties. The results suggest that beta-blockers may compete for the same binding sites with ouabain in their inhibition of the Na+/K+-ATPase. These actions may contribute to the mechanism for some of their cardiac effects, especially their proarrhythmic and arrhythmogenic actions.
No takes yet. Share an insight, caveat, or question.
Almotrefi et al. (2001) studied this question. Beta-blockers was evaluated on Displacement binding assays with [3H]-ouabain. Beta-blockers showed concentration-dependent receptor occupancy at ouabain binding sites on Na+/K+-ATPase, with propranolol, metoprolol, and sotalol showing the strongest binding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: